Your browser doesn't support javascript.
loading
The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort.
Franklin, Hannah D; Russell, Lucy L; Peakman, Georgia; Greaves, Caroline V; Bocchetta, Martina; Nicholas, Jennifer; Poos, Jackie; Convery, Rhian S; Cash, David M; van Swieten, John; Jiskoot, Lize; Moreno, Fermin; Sanchez-Valle, Raquel; Borroni, Barbara; Laforce, Robert; Masellis, Mario; Tartaglia, Maria Carmela; Graff, Caroline; Galimberti, Daniela; Rowe, James B; Finger, Elizabeth; Synofzik, Matthis; Vandenberghe, Rik; de Mendonça, Alexandre; Tagliavini, Fabrizio; Santana, Isabel; Ducharme, Simon; Butler, Chris; Gerhard, Alex; Levin, Johannes; Danek, Adrian; Otto, Markus; Sorbi, Sandro; Le Ber, Isabelle; Pasquier, Florence; Rohrer, Jonathan D.
Afiliación
  • Franklin HD; Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
  • Russell LL; Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
  • Peakman G; Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
  • Greaves CV; Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
  • Bocchetta M; Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
  • Nicholas J; Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.
  • Poos J; Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.
  • Convery RS; Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
  • Cash DM; Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
  • van Swieten J; Centre for Medical Image Computing, Department of Medical Physics and Biomedical Engineering, University College London, London, United Kingdom.
  • Jiskoot L; Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.
  • Moreno F; Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
  • Sanchez-Valle R; Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.
  • Borroni B; Cognitive Disorders Unit, Department of Neurology, Donostia University Hospital, San Sebastian, Gipuzkoa, Spain.
  • Laforce R; Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Gipuzkoa, Spain.
  • Masellis M; Alzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Institut d'Investigacións Biomèdiques August Pi I Sunyer, University of Barcelona, Barcelona, Spain.
  • Tartaglia MC; Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
  • Graff C; Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, CHU de Québec, and Faculté de Médecine, Université Laval, Québec, QC, Canada.
  • Galimberti D; Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Canada.
  • Rowe JB; Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada.
  • Finger E; Center for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Bioclinicum, Karolinska Institutet, Solna, Sweden.
  • Synofzik M; Unit for Hereditary Dementias, Theme Aging, Karolinska University Hospital, Solna, Sweden.
  • Vandenberghe R; Fondazione Ca' Granda, IRCCS Ospedale Policlinico, Milan, Italy.
  • de Mendonça A; University of Milan, Centro Dino Ferrari, Milan, Italy.
  • Tagliavini F; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
  • Santana I; Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada.
  • Ducharme S; Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany.
  • Butler C; Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
  • Gerhard A; Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium.
  • Levin J; Neurology Service, University Hospitals Leuven, Leuven, Belgium.
  • Danek A; Leuven Brain Institute, KU Leuven, Leuven, Belgium.
  • Otto M; Laboratory of Neurosciences, Institute of Molecular Medicine, Faculty of Medicine, University of Lisbon, Lisbon, Portugal.
  • Sorbi S; Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy.
  • Le Ber I; University Hospital of Coimbra (HUC), Neurology Service, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
  • Pasquier F; Center for Neuroscience and Cell Biology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
  • Rohrer JD; Department of Psychiatry, McGill University Health Centre, McGill University, Montreal, Québec, Canada.
Alzheimers Res Ther ; 13(1): 127, 2021 07 12.
Article en En | MEDLINE | ID: mdl-34253227
BACKGROUND: Although social cognitive dysfunction is a major feature of frontotemporal dementia (FTD), it has been poorly studied in familial forms. A key goal of studies is to detect early cognitive impairment using validated measures in large patient cohorts. METHODS: We used the Revised Self-Monitoring Scale (RSMS) as a measure of socioemotional sensitivity in 730 participants from the genetic FTD initiative (GENFI) observational study: 269 mutation-negative healthy controls, 193 C9orf72 expansion carriers, 193 GRN mutation carriers and 75 MAPT mutation carriers. All participants underwent the standardised GENFI clinical assessment including the 'CDR® plus NACC FTLD' scale and RSMS. The RSMS total score and its two subscores, socioemotional expressiveness (EX score) and modification of self-presentation (SP score) were measured. Volumetric T1-weighted magnetic resonance imaging was available from 377 mutation carriers for voxel-based morphometry (VBM) analysis. RESULTS: The RSMS was decreased in symptomatic mutation carriers in all genetic groups but at a prodromal stage only in the C9orf72 (for the total score and both subscores) and GRN (for the modification of self-presentation subscore) groups. RSMS score correlated with disease severity in all groups. The VBM analysis implicated an overlapping network of regions including the orbitofrontal cortex, insula, temporal pole, medial temporal lobe and striatum. CONCLUSIONS: The RSMS indexes socioemotional impairment at an early stage of genetic FTD and may be a suitable outcome measure in forthcoming trials.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Demencia Frontotemporal Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: Alzheimers Res Ther Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Demencia Frontotemporal Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: Alzheimers Res Ther Año: 2021 Tipo del documento: Article